Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
Proton RahmanIain B McInnesAtul A DeodharLarissa Valor-MéndezPhillip J MeaseMay ShawiDaniel J CuaJonathan P SherlockAlexa P KollmeierXie L XuShihong ShengChristopher T RitchlinDennis G McGonaglePublished in: Clinical rheumatology (2024)
ClinicalTrials.gov ( https://clinicaltrials.gov ) NCT03158285; Registered: May 16, 2017. Key Points • At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR). • Achieving ER was associated with achieving DR and vice versa through the end of study. • Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported outcomes.
Keyphrases
- patient reported outcomes
- editorial comment
- endoplasmic reticulum
- estrogen receptor
- breast cancer cells
- newly diagnosed
- juvenile idiopathic arthritis
- end stage renal disease
- single molecule
- ejection fraction
- randomized controlled trial
- clinical trial
- chronic kidney disease
- systemic lupus erythematosus
- peritoneal dialysis
- rheumatoid arthritis
- patient reported